263 related articles for article (PubMed ID: 10940280)
1. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
Frieri G; Giacomelli R; Pimpo M; Palumbo G; Passacantando A; Pantaleoni G; Caprilli R
Gut; 2000 Sep; 47(3):410-4. PubMed ID: 10940280
[TBL] [Abstract][Full Text] [Related]
2. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
3. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
Olaisen M; Spigset O; Flatberg A; Granlund AVB; Brede WR; Albrektsen G; Røyset ES; Gilde B; Sandvik AK; Martinsen TC; Fossmark R
Aliment Pharmacol Ther; 2019 May; 49(10):1301-1313. PubMed ID: 30895635
[TBL] [Abstract][Full Text] [Related]
4. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
[TBL] [Abstract][Full Text] [Related]
5. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
6. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
[TBL] [Abstract][Full Text] [Related]
7. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment.
Frieri G; Pimpo MT; Palumbo GC; Onori L; Viscido A; Latella G; Galletti B; Pantaleoni GC; Caprilli R
Aliment Pharmacol Ther; 1999 Nov; 13(11):1413-7. PubMed ID: 10571596
[TBL] [Abstract][Full Text] [Related]
8. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Li J; Chen C; Cao XN; Wang GH; Hu JB; Wang J
J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):59-65. PubMed ID: 24496680
[TBL] [Abstract][Full Text] [Related]
10. Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.
Zezos P; Patsiaoura K; Nakos A; Mpoumponaris A; Vassiliadis T; Giouleme O; Pitiakoudis M; Kouklakis G; Evgenidis N
Colorectal Dis; 2014 Dec; 16(12):O420-30. PubMed ID: 25040651
[TBL] [Abstract][Full Text] [Related]
11. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis.
Odze R; Antonioli D; Peppercorn M; Goldman H
Am J Surg Pathol; 1993 Sep; 17(9):869-75. PubMed ID: 8352372
[TBL] [Abstract][Full Text] [Related]
12. Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.
van de Meeberg MM; Schultheiss JPD; Oldenburg B; Fidder HH; Huitema ADR
Digestion; 2020; 101(3):245-261. PubMed ID: 31013494
[TBL] [Abstract][Full Text] [Related]
13. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
14. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
Le Berre C; Roda G; Nedeljkovic Protic M; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):363-378. PubMed ID: 31498003
[No Abstract] [Full Text] [Related]
15. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R
Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584
[TBL] [Abstract][Full Text] [Related]
16. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.
Matthis AL; Zhang B; Denson LA; Yacyshyn BR; Aihara E; Montrose MH
Inflamm Bowel Dis; 2016 Aug; 22(8):1793-802. PubMed ID: 27416043
[TBL] [Abstract][Full Text] [Related]
17. Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity.
Pearl DS; Shah K; Whittaker MA; Nitch-Smith H; Brown JF; Shute JK; Trebble TM
J Crohns Colitis; 2013 Jul; 7(6):481-9. PubMed ID: 22974822
[TBL] [Abstract][Full Text] [Related]
18. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
Stobaugh DJ; Deepak P; Thorpe M; Hannon B; Ehrenpreis ED
Inflamm Bowel Dis; 2013 Feb; 19(2):301-8. PubMed ID: 22644716
[TBL] [Abstract][Full Text] [Related]
19. 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice.
Tang H; Xiang D; Wang F; Mao J; Tan X; Wang Y
Mol Med Rep; 2017 Mar; 15(3):1117-1122. PubMed ID: 28138699
[TBL] [Abstract][Full Text] [Related]
20. Altered colonic mucosal Polyunsaturated Fatty Acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiology.
Masoodi M; Pearl DS; Eiden M; Shute JK; Brown JF; Calder PC; Trebble TM
PLoS One; 2013; 8(10):e76532. PubMed ID: 24204637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
